Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

NanoString nCounter Mouse PanCancer Immune Profiling of CT26 tumors following chronic in vitro PMS2 inhibition and in vivo anti-PD-1 treatment

ABSTRACT: NanoString nCounter immune profiling revealed that PMS2 inhibitor NP1867-pretreated tumours mounted an enhanced immune response to anti-PD-1 therapy, characterized by increased infiltration of lymphocytes, including T cells and cytotoxic populations, together with enrichment of multiple immune-related pathways. These included adaptive immune responses, antigen processing and presentation, MHC signaling, and interferon pathways, indicating that NP1867 pretreatment primes tumors for improved immunological responsiveness to PD-1 blockade.

ORGANISM(S): Mus musculus

PROVIDER: GSE326327 | GEO | 2026/04/21

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

NanoString nCounter Mouse PanCancer Immune Profiling of CT26 tumors following chronic in vitro PMS2 inhibition and in vivo anti-PD-1 treatment

Project description:NanoString nCounter Mouse PanCancer Immune Profiling of CT26 tumors following chronic in vitro PMS2 inhibition and in vivo anti-PD-1 treatment

| PRJNA1445117 | ENA

nCounter PanCancer mouse immune profiling in CT26-bearing mouse tumor treated with DSP-0509 combined with anti PD-1 antibody

Project description:nCounter PanCancer mouse immune profiling in CT26-bearing mouse tumor treated with DSP-0509 combined with anti PD-1 antibody

| PRJNA896120 | ENA

nCounter PanCancer mouse immune profiling in CT26-bearing mouse tumor treated with DSP-0509 combined with anti PD-1 antibody

Project description:Combinatio of DSP-0509, small molecule TLR7 agonist, with anti PD-1 antibody enhanced anti-tumor inflammatory tumor microenvironment in CT26 tumor.

2023-01-24 | GSE216890 | GEO

Nanostring nCounter Mouse PanCancer Immune Profiling analysis of murine tumor tissues

Project description:Nanostring nCounter Mouse PanCancer Immune Profiling analysis of murine tumor tissues

| PRJNA1458243 | ENA

NanoString Human PC3 nCounter PanCancer IO 360 panel

Project description:NanoString Human PC3 nCounter PanCancer IO 360 panel

| PRJNA772256 | ENA

NanoString nCounter Gene Expression of keratinocytes pretreated with HSP90 inhibitor and challenged with 12-O-tetradecanoylphorbol-13-acetate (TPA)

Project description:The mRNA levels of 579 inflammatory genes were analyzed with Nanostring nCounter Human Immunology Panel in primary human keratinocytes pretreated with RGRN-305 (HSP90 inhibitor) and challenged with TPA

2023-01-31 | GSE221998 | GEO

Transcriptomic analsyis of Epithelial and Mesenchymal carcinoma cells using the nCounter PanCancer Immune Profiling panel (Nanostring Technologies) [mouse]

Project description:We undertook to determine whether carcinoma cells residing in the epithelial or quasi-mesenchymal phenotypic states differ in their expression of immunomodulatory markers. To do so, we used the nCounter PanCancer Immune Profiling Panel (Nanostring Technologies)to perform transcriptomic analyses of the E and qM mammary carcinoma cells; these cells were either cultured in vitro or prepared by FACS sorting of GFP-labelled carcinoma cells from their corresponding tumors

2021-09-15 | GSE161746 | GEO

NanoString nCounter Mouse PanCancer Immune Profiling of B16F10 tumors treated with DC vaccines

Project description:NanoString nCounter Mouse PanCancer Immune Profiling of B16F10 tumors treated with DC vaccines

| PRJNA1460367 | ENA

Nanostring nCounter Mouse PanCancer Immune Profiling analysis of murine tumor tissues

Project description:The immunosuppressive tumor microenvironment (TME) contributes to resistance against checkpoint inhibitors. However, the precise factors that shape the immune contexture of the TME remain elusive. Here, we report that Single-Stranded DNA Binding Protein 4 (SSBP4), a previously uncharacterized protein, suppresses intratumoral T-cell activation by promoting excessive cholesteryl ester production in tumor cells. Overexpression of SSBP4 in tumor cells decreased T-cell infiltration and accelerated tumor growth in murine syngeneic tumor models. Conversely, genetic ablation of SSBP4 in tumor cells enhanced T-cell infiltration and inhibited tumor growth in a CD8+ T cell–-dependent manner. Mechanistically, SSBP4 upregulated cholesterol synthesis genes, leading to increased production of cholesterol and cholesteryl esters in tumor cells, which directly suppressed CD8+ T-cell activation and function. Furthermore, SSBP4 abrogation significantly improved the efficacy of anti-PD-1 treatment. Thus, in this study, we have identified SSBP4 as a cancer cell–intrinsic regulator of cholesterol metabolism that contributes to tumor immune evasion. Immune-related gene expression was quantified using the Nanostring Mouse PanCancer Immune Profiling panel. Total RNA was isolated from the C57BL/6 SSBP4-wildtype or knockout B16F10 tumors on Day 15 post tumor inoculation. RNA was hybridized, scanned on a Nanostring Digital Analyzer, and raw RCC files were generated. Raw count data were processed and normalized in nSolver or ROSALIND software for downstream immune transcriptome profiling.

2026-04-30 | GSE329266 | GEO

Transcriptomic analsyis of Epithelial and Mesenchymal carcinoma cells using the nCounter PanCancer Immune Profiling panel (Nanostring Technologies) [human]

Project description:We undertook to determine whether carcinoma cells residing in the epithelial or quasi-mesenchymal phenotypic states differ in their expression of immunomodulatory markers.To demonstrate a direct association between activation of the EMT program and immunosuppression, we induced EMT programs in vitro in an array of cultured BrCa cell lines via the doxycycline-induced expression of various EMT-inducing transcription factors (EMT-TFs) and proceeded to determine whether activation of the EMT program also alters cell-intrinisc immuno-modulatory markers To do so, we used the nCounter PanCancer Immune Profiling Panel (Nanostring Technologies)to perform transcriptomic analyses of control E cells or those induced to undergo an EMT

2021-09-15 | GSE161747 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data